Mirum Pharmaceuticals ( (MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on transforming the treatment of rare diseases affecting children and adults, with a portfolio that includes three approved medications and a late-stage pipeline targeting several rare conditions.
In its third quarter of 2025, Mirum Pharmaceuticals reported a total revenue of $133 million, reflecting robust growth and strong commercial momentum. The company has updated its full-year revenue guidance to a range of $500 to $510 million, indicating confidence in its ongoing performance and market position.
Key financial highlights include a 56% increase in net product sales for LIVMARLI, reaching $92.2 million, and a 31% growth in Bile Acid Medicines sales, totaling $40.8 million. The company has also made significant progress in its pipeline, with completed enrollment in the VISTAS PSC study and the initiation of a Phase 2 study for Fragile X Syndrome. Operating expenses rose to $130.4 million, driven by increased research and development activities, yet the company maintained a net income of $2.9 million for the quarter.
Looking ahead, Mirum Pharmaceuticals is poised for continued growth, with multiple catalysts expected in 2026 and 2027. The company’s management remains optimistic about its strategic initiatives and financial outlook, as it continues to advance its pipeline and expand its market presence.